Navigation Links
Preclinical tests shows agent stops 'slippery' proteins from binding, causing Ewing sarcoma
Date:5/15/2013

WASHINGTON Continuous infusion of a novel agent not only halted the progression of Ewing sarcoma in rats, while some tumors also regressed to the point that cancer cells could not be detected microscopically, say researchers at Georgetown Lombardi Comprehensive Cancer Center. Their study, which will be presented at the 2013 annual meeting of the American Society of Clinical Oncology, provides pre-clinical evidence necessary to initiate a clinical trial.

"This agent has the potential to be more effective, and considerably less toxic, than the current drugs now used to treat this rare cancer," says the study's lead investigator, Jeffrey Toretsky, MD, a pediatric oncologist and researcher at Georgetown Lombardi, part of Georgetown University Medical Center.

The agent, (S)-YK-4-279, was developed by Toretsky and his colleagues, including scientists in GUMC's Center for Drug Discovery. Based on early promising studies of the compound, Toretsky established TDP Biotherapeutics, Inc. to manufacture the agent. Toretsky says TDP Biotherapeutics, Inc. is preparing a U.S. Food and Drug Administration (FDA) investigational new drug (IND) application for (S)-YK-4-279 so that a clinical trial can be initiated.

In the United States, about 500 children and young adults are diagnosed with the cancer annually, and they are treated with a combination of five different chemotherapy drugs. Between 60 to 70 percent of patients survive more than five years, but with many late effects from therapy. Few treatments lead to a cure for patients whose cancer progresses, Toretsky says.

Ewing sarcoma is caused by the exchange of DNA between two chromosomes. The resulting EWSR1-FLI1 gene produces a fusion protein, EWS-FLI1, responsible for development of the cancer. In 2006, Toretsky and his team discovered that the fusion protein binds to another protein, RNA helicase A (RHA), which is important for cancer progression.

The (S)-YK-4-279 agent they developed is considered unique because it stops the two proteins EWS-FLI1 and RHA from interacting. "Scientists have long thought it impossible to block protein-protein interaction because the surface of these proteins are too slippery and flexible for a drug to bind to," Toretsky says. "Our agent challenges that conventional thinking."

To test the agent, the researchers developed a rat model of Ewing sarcoma and figured out how to deliver a continuous drip of the drug to the animals. "We found that cancer cells need a continuous exposure at low concentrations for the drug to be of maximum effectiveness," Toretsky says. "And this strategy works extremely well in these animal models. The drug appears to be very successful."

Toretsky is an inventor on a patent application that has been filed by Georgetown University related to the technology described. He has an ownership interest in TDP Biotherapeutics, to which the technology has been licensed for research and development.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
2. Genetically-engineered preclinical models predict pharmacodynamic response
3. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
4. Charm Sciences Announces Six WET® (Water Extraction Technology) Mycotoxin Tests
5. Half of People With Hepatitis C Dont Complete Needed Tests: CDC
6. All hospitals should require drug, alcohol tests for physicians
7. Consumer Reports Tests: Bacteria on Turkey Raised Without Antibiotics Showed Significantly Less Antibiotic Resistance than Bacteria Conventional Turkey
8. Battery of tests on cancer cells shows them as squishy, yet tactically strong
9. PeopleKeys Personality Tests Give Job Seekers a Competitive Advantage
10. Doctors Order Fewer Lab Tests When They Know the Cost
11. Naturally-occurring substance proves effective against deadly skin cancer in laboratory tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Texas ... week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. ... The company had 800 customers and 2,250 RCEs at the time of acquisition. ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... clinic serving San Francisco and environs, is proud to announce an upgrade to ... information on the upgraded Yelp page on topics as diverse as Platelet Rich ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards ... of International Social Design Awards. , The 7th A' Social Design Award ... and Institutions worldwide with realized projects and conceptual works. , The first phase ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... ... 2017 , ... ODH, Inc.™ announced today it will exhibit and speak ... City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will ... Medicaid population health management. , ODH will also have an exhibit booth where attendees ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Juan Monteverde ... Associates PC , a boutique securities firm headquartered at ... City , announces that a class action lawsuit ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" ... Company,s securities between July 23, 2015 and December 30, 2016, ...
(Date:2/24/2017)... MELBOURNE , Australien, 24. Februar 2017 /PRNewswire/ ... innovatives, diversifiziertes Unternehmen des Gesundheitsbereiches, ist erfreut, für ... Vergleich mit dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen ... BioMedical und Aktualisierung zum Wachstum" finden Sie ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017  This ... US$ Thousand by the following Products: ... analyzed in the report include Pharmaceuticals, and Agrochemicals. The ... Japan , Europe , ... provided for the period 2015 through 2022. Also, a ...
Breaking Medicine Technology: